Phase I Clinical Study to Evaluate Safety, Tolerance and Pharmacokinetics of SY-005 After Single-dose/Multiple-doses Incremental Intravenous Injection in Healthy Subjects
Latest Information Update: 07 Jun 2021
At a glance
- Drugs SY 005 (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Sponsors Yabao Pharmaceutical Group
Most Recent Events
- 29 Apr 2021 Status changed from recruiting to completed.
- 06 Jan 2020 New trial record